AI meets multi-omics to revolutionize healthcare from Dubai to the world.
DUBAI, UAE – June 2025 — BioAro Inc., a leading Canadian biotechnology and precision medicine company, has officially introduced its groundbreaking PanOmiQ™ Research platform to the UAE market—signaling a new era for AI-integrated genomics and drug discovery across the Middle East and beyond.
Unveiled globally at the 2025 BIO International Convention in Boston, PanOmiQ™ Research is now poised to transform healthcare delivery in the UAE, a country rapidly emerging as a hub for innovation in life sciences and smart healthcare. The platform represents the world’s first unified, multilingual, AI-powered ecosystem connecting genomics, proteomics, metabolomics, and microbiome data into a real-time clinical and drug discovery interface.
“Dubai is at the forefront of adopting next-generation medical technologies. With PanOmiQ™ Research, we’re aligning with the UAE’s vision for predictive, personalized healthcare powered by AI,” said Dr. Anmol S. Kapoor, Founder and CEO of BioAro Inc.
Already known for completing clinical-grade genome analysis in under 2 hours and delivering variant reports in minutes, PanOmiQ™ now adds new capabilities that address critical challenges in early disease detection, longevity research, and precision therapeutics—key focus areas for UAE’s national health strategy.
The platform’s newly launched Deep Drug Discovery module uses AI to decode biological data into actionable pharmaceutical candidates, accelerating drug development with unprecedented accuracy and speed. Using ADMET modeling, structure-based screening, and pathway mapping, PanOmiQ™ enables local researchers and biotech firms to fast-track innovation.
PanOmiQ™ now offers full clinical report generation in Arabic, empowering hospitals, government health programs, and international research partnerships based in the UAE. Its flexible deployment options—cloud-based or on-premise—cater perfectly to the digital infrastructure and regulatory frameworks of the Gulf region.
“Whether in Dubai, Riyadh, or Doha, PanOmiQ™ now speaks your language—scientifically and literally,” added Dr. Kapoor.
With PanOmiQ™ Research, BioAro is inviting UAE universities, healthcare institutions, and public health authorities to access the same advanced omics tools used globally. The platform supports high-throughput analytics for population-scale genomics, secure cross-border research, and predictive modeling for non-communicable diseases—now the leading cause of mortality across the GCC.
“This is about studying disease not in isolation, but at the system level—something we believe is essential to tackling rising health challenges in the region,” said Dr. Raja Balraj Singh, Chief Scientific Officer at BioAro.
As the UAE’s healthcare system scales to meet the demands of a growing, aging population, PanOmiQ™ delivers the tools to shift from reactive care to proactive intervention. It decodes biological complexity at machine speed—empowering clinicians and scientists to make decisions faster and with greater precision.
With the UAE already investing heavily in AI, genomics, and biotech, BioAro’s expansion into the region is a timely and strategic step. PanOmiQ™ is more than a platform—it is a catalyst for the next generation of healthcare innovation in the Emirates.